Fundraising Fox
/Companies
Sign in

Solu

21 employees on LinkedIn · 3 known investors

Find your way into Solu

Sign up to see every warm intro you have to Solu

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Solu team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Solu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.

BiotechHealthtech

Founders & leadership

PVPhil Vickers
Phil VickersCEO / Leadership
MBMichael Boretti
Michael BorettiLeadershipMichael Boretti has over 15 years of experience in biotech, with expertise in corporate strategy, business development, and operations across discovery through clinical-stage companies. He leads Solu Therapeutics, which is developing bifunctional antibody therapeutics targeting GPCRs, ion channels, and other cell surface proteins for oncology, immunology, and pain indications.
BTBrandon Turunen
Brandon TurunenLeadershipBrandon Turunen is Chief Scientific Officer of Solu Therapeutics, a clinical-stage biotech company developing bifunctional antibody therapeutics targeting oncology, immunology, and inflammation. He has led multidisciplinary drug discovery teams and advanced first-in-class programs through translational development and into clinical trials.
SSSergio Santillana
Sergio SantillanaLeadership
EMEnda Moran
Enda MoranLeadershipEnda Moran is a healthcare executive with experience in biologics, vaccine development, and commercialization across pharma and biotech, and has led global teams on drug development initiatives.
KHKelly Honohan
Kelly HonohanLeadership
MTMarissa Timothy
Marissa TimothyLeadershipMarissa Timothy is a clinical operations leader with experience overseeing trials across Phase I-IV oncology and immunology programs at biotech and pharmaceutical companies, with expertise in site selection, vendor management, and FDA compliance.
JPJohn Pribis
John PribisLeadershipJohn Pribis is a leader at Solu Therapeutics, a clinical-stage biotech company developing bifunctional antibody therapeutics targeting oncology, immunology, inflammation, and pain.

Investors · 3

Longwood Fundlisted by Longwood FundBoston

How we know: Longwood Fund's portfolio page · the VCSheet dataset · Not right? Tell us

Pappas CapitalreportedResearch Triangle Park · $100K – $6M

How we know: funding news · Not right? Tell us

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Solu Therapeutics Closes $41M Series A Financingfinsmes.com · Apr 2025Solu Therapeutics Raises $31M in Seed Fundingfinsmes.com · Aug 2023

Frequently asked questions

What does Solu do?
Solu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Who are Solu's investors?
Solu's investors include Astellas Venture Management LLC, Longwood Fund, Pappas Capital.